Turning Point Therapeutics
About Turning Point Therapeutics
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
At Turning Point, we’re driven by many things: Excellent science. Novel structure-based design. Targeted treatment approaches. A team that we’re excited to work alongside every day. But above all else, what drives us is our desire to bring differentiated therapies to patients as rapidly as we can.
31 articles about Turning Point Therapeutics
-
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio
8/17/2022
Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.
-
Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics
8/16/2022
Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) (“Turning Point”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and the receipt of merger control clearance from the Federal Cartel Office of Germany (“FCO”), in connection with the previously announced offer (the “Offer”) to acquire all outstanding shares of common stock of Turning Point at a price of $76.00 per share.
-
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
8/8/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended June 30, 2022 and provided operational updates.
-
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
7/27/2022
Turning Point Therapeutics, Inc. announced receipt of positive feedback from the U.S. Food and Drug Administration at a pre-New Drug Application meeting completed within the second quarter.
-
Bristol Myers Squibb Announces Extension of Turning Point Tender Offer
7/19/2022
Bristol Myers Squibb (NYSE:BMY) today has announced that Rhumba Merger Sub Inc. (“Offeror”), a wholly owned subsidiary of Bristol Myers Squibb, has extended the expiration date of its offer (the “Offer”) to acquire (the “Acquisition”) all of the outstanding shares of common stock, par value $0.0001 per share (“Common Stock”), of Turning Point Therapeutics, Inc.
-
A new report by PwC projects that the second half of this year will see a “flurry of deals activity across all areas of the sector.”
-
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
6/24/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), and The University of Texas MD Anderson Cancer Center today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.
-
Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.
-
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company
6/3/2022
Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to Launch in 2023.
-
Turning Point Therapeutics to Participate in Upcoming Investor Conferences - May 26, 2022
5/26/2022
Turning Point Therapeutics, Inc. announced that President and CEO Athena Countouriotis, M.D., will participate in the Jefferies Healthcare Conference on June 8 and the 43rd Annual Goldman Sachs Healthcare Conference on June 14.
-
Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer
5/16/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the appointment of Steve Sabus as Chief Commercial Officer, effective as of May 31, 2022.
-
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates
5/10/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided operational updates.
-
Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy
5/10/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today announced the U.S. Food and Drug Administration (FDA) granted an eighth regulatory designation, and third Breakthrough Therapy designation, to lead drug candidate repotrectinib.
-
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
5/5/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater China and South Korea.
-
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
4/28/2022
Turning Point Therapeutics, Inc. and Zai Lab announced topline data for repotrectinib within the China region from the previously disclosed Phase 1/2 TRIDENT-1 study dataset.
-
Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study
4/12/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), today announced positive topline results from the registrational TRIDENT-1 study across all four ROS1-positive advanced non-small cell lung cancer (NSCLC) cohorts, as reported by Blinded Independent Central Review (BICR).
-
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
3/29/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Brian Sun, M.S., J.D. as its incoming Senior Vice President and General Counsel, effective as of April 11, 2022.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population
3/21/2022
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), today announced the company has achieved its enrollment target of 40 patients in the EXP-6 cohort of the phase 1/2 registrational TRIDENT-1 study. EXP-6 is comprised of NTRK-positive TKI-pretreated advanced solid tumor patients.